MiMedx Group (MDXG) Competitors

$3.60 -0.09 (-2.44%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$3.63 +0.03 (+0.83%)

As of 05/8/2026 07:59 PM Eastern

MDXG vs. ESTA, NVCR, EYE, AORT, and PRCT

Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Establishment Labs (ESTA), NovoCure (NVCR), National Vision (EYE), Artivion (AORT), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry.

How does MiMedx Group compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Establishment Labs had 11 more articles in the media than MiMedx Group. MarketBeat recorded 19 mentions for Establishment Labs and 8 mentions for MiMedx Group. Establishment Labs' average media sentiment score of 0.32 beat MiMedx Group's score of -0.09 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Comparatively, 1.7% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MiMedx Group has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	9.99	-$51.06M	-$1.49	N/A
MiMedx Group	$418.63M	1.28	$48.58M	$0.20	18.00

Establishment Labs has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Establishment Labs presently has a consensus target price of $87.14, indicating a potential upside of 21.42%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 136.11%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has a net margin of 7.88% compared to Establishment Labs' net margin of -19.05%. MiMedx Group's return on equity of 21.03% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-202.78%	-12.39%
MiMedx Group	7.88%	21.03%	15.92%

Summary

MiMedx Group beats Establishment Labs on 11 of the 15 factors compared between the two stocks.

How does MiMedx Group compare to NovoCure?

NovoCure (NASDAQ:NVCR) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

NovoCure presently has a consensus target price of $27.29, indicating a potential upside of 52.52%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 136.11%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -25.66%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
MiMedx Group	7.88%	21.03%	15.92%

In the previous week, NovoCure had 5 more articles in the media than MiMedx Group. MarketBeat recorded 13 mentions for NovoCure and 8 mentions for MiMedx Group. NovoCure's average media sentiment score of 0.12 beat MiMedx Group's score of -0.09 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

NovoCure has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

MiMedx Group has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.16	-$136.23M	-$1.53	N/A
MiMedx Group	$418.63M	1.28	$48.58M	$0.20	18.00

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Comparatively, 1.7% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

MiMedx Group beats NovoCure on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to National Vision?

MiMedx Group (NASDAQ:MDXG) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

MiMedx Group presently has a consensus target price of $8.50, indicating a potential upside of 136.11%. National Vision has a consensus target price of $32.08, indicating a potential upside of 39.71%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe MiMedx Group is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
National Vision	0 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.54

MiMedx Group has a net margin of 7.88% compared to National Vision's net margin of 1.49%. MiMedx Group's return on equity of 21.03% beat National Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
National Vision	1.49%	5.15%	2.22%

In the previous week, MiMedx Group had 3 more articles in the media than National Vision. MarketBeat recorded 8 mentions for MiMedx Group and 5 mentions for National Vision. National Vision's average media sentiment score of 1.07 beat MiMedx Group's score of -0.09 indicating that National Vision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
National Vision	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

MiMedx Group has higher earnings, but lower revenue than National Vision. MiMedx Group is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.28	$48.58M	$0.20	18.00
National Vision	$1.99B	0.93	$29.60M	$0.37	62.05

79.2% of MiMedx Group shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by company insiders. Comparatively, 2.7% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MiMedx Group beats National Vision on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Artivion?

MiMedx Group (NASDAQ:MDXG) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by company insiders. Comparatively, 6.3% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MiMedx Group has a net margin of 7.88% compared to Artivion's net margin of 2.55%. MiMedx Group's return on equity of 21.03% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
Artivion	2.55%	7.21%	3.65%

MiMedx Group presently has a consensus target price of $8.50, indicating a potential upside of 136.11%. Artivion has a consensus target price of $47.83, indicating a potential upside of 88.59%. Given MiMedx Group's higher possible upside, equities research analysts plainly believe MiMedx Group is more favorable than Artivion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

MiMedx Group has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

In the previous week, Artivion had 8 more articles in the media than MiMedx Group. MarketBeat recorded 16 mentions for Artivion and 8 mentions for MiMedx Group. Artivion's average media sentiment score of 0.09 beat MiMedx Group's score of -0.09 indicating that Artivion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artivion	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has higher earnings, but lower revenue than Artivion. MiMedx Group is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.28	$48.58M	$0.20	18.00
Artivion	$441.33M	2.79	$9.77M	$0.24	105.68

Summary

Artivion beats MiMedx Group on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to PROCEPT BioRobotics?

MiMedx Group (NASDAQ:MDXG) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by company insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiMedx Group has a net margin of 7.88% compared to PROCEPT BioRobotics' net margin of -31.82%. MiMedx Group's return on equity of 21.03% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

MiMedx Group presently has a consensus target price of $8.50, indicating a potential upside of 136.11%. PROCEPT BioRobotics has a consensus target price of $41.45, indicating a potential upside of 63.21%. Given MiMedx Group's stronger consensus rating and higher probable upside, research analysts plainly believe MiMedx Group is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43

MiMedx Group has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

In the previous week, MiMedx Group had 6 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 8 mentions for MiMedx Group and 2 mentions for PROCEPT BioRobotics. MiMedx Group's average media sentiment score of -0.09 beat PROCEPT BioRobotics' score of -0.31 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.28	$48.58M	$0.20	18.00
PROCEPT BioRobotics	$308.05M	4.69	-$95.57M	-$1.82	N/A

Summary

MiMedx Group beats PROCEPT BioRobotics on 12 of the 16 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$549.61M	$3.37B	$6.25B	$12.13B
Dividend Yield	N/A	2.25%	2.78%	5.20%
P/E Ratio	18.00	15.49	20.77	25.39
Price / Sales	1.28	299.33	534.44	75.98
Price / Cash	6.66	124.38	43.29	53.47
Price / Book	2.21	7.32	9.96	6.84
Net Income	$48.58M	$24.23M	$3.55B	$333.46M
7 Day Performance	-2.17%	2.20%	3.48%	3.09%
1 Month Performance	-10.67%	4.45%	4.13%	7.12%
1 Year Performance	-49.44%	78.68%	41.79%	41.27%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	3.6772 of 5 stars	$3.60 -2.4%	$8.50 +136.1%	N/A	$549.61M	$418.63M	18.00	870	News Coverage
ESTA Establishment Labs	2.866 of 5 stars	$71.23 +1.4%	$86.86 +21.9%	N/A	$2.11B	$211.08M	N/A	1,004	News Coverage Earnings Report Analyst Forecast Insider Trade
NVCR NovoCure	3.2837 of 5 stars	$16.21 -4.3%	$27.29 +68.3%	N/A	$1.88B	$674.41M	N/A	1,605	Analyst Revision
EYE National Vision	3.7135 of 5 stars	$22.07 +0.7%	$31.21 +41.4%	N/A	$1.75B	$1.99B	59.51	13,138	News Coverage Positive News Upcoming Earnings
AORT Artivion	4.194 of 5 stars	$35.33 -0.6%	$51.00 +44.3%	N/A	$1.71B	$441.33M	176.80	1,800	Trending News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. ESTA, NVCR, EYE, AORT, and PRCT

How does MiMedx Group compare to Establishment Labs?

Summary

How does MiMedx Group compare to NovoCure?

Summary

How does MiMedx Group compare to National Vision?

Summary

How does MiMedx Group compare to Artivion?

Summary

How does MiMedx Group compare to PROCEPT BioRobotics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. ESTA, NVCR, EYE, AORT, and PRCT

How does MiMedx Group compare to Establishment Labs?

Does the media prefer ESTA or MDXG?

Do institutionals and insiders have more ownership in ESTA or MDXG?

Which has preferable valuation & earnings, ESTA or MDXG?

Which has more volatility and risk, ESTA or MDXG?

Do analysts recommend ESTA or MDXG?

Is ESTA or MDXG more profitable?

Summary

How does MiMedx Group compare to NovoCure?

Do analysts recommend NVCR or MDXG?

Is NVCR or MDXG more profitable?

Does the media prefer NVCR or MDXG?

Which has more volatility and risk, NVCR or MDXG?

Which has preferable valuation & earnings, NVCR or MDXG?

Do institutionals and insiders have more ownership in NVCR or MDXG?

Summary

How does MiMedx Group compare to National Vision?

Do analysts prefer MDXG or EYE?

Is MDXG or EYE more profitable?

Does the media favor MDXG or EYE?

Which has more risk and volatility, MDXG or EYE?

Which has higher valuation and earnings, MDXG or EYE?

Do insiders & institutionals have more ownership in MDXG or EYE?

Summary

How does MiMedx Group compare to Artivion?

Do insiders & institutionals have more ownership in MDXG or AORT?

Is MDXG or AORT more profitable?

Do analysts prefer MDXG or AORT?

Which has more risk and volatility, MDXG or AORT?

Does the media favor MDXG or AORT?

Which has higher valuation and earnings, MDXG or AORT?

Summary

How does MiMedx Group compare to PROCEPT BioRobotics?

Do institutionals & insiders have more ownership in MDXG or PRCT?

Is MDXG or PRCT more profitable?

Do analysts prefer MDXG or PRCT?

Which has more risk & volatility, MDXG or PRCT?

Does the media favor MDXG or PRCT?

Which has stronger earnings and valuation, MDXG or PRCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools